Graph AI

Graph AI announced $13.3M in Series A financing on September 10, 2026. Graph AI raised a $13.3 million Series A led by Insight Partners to expand its AI-native pharmacovigilance platform in the US and Europe.

Round details

The financing includes backing from Insight Partners, Bessemer Venture Partners. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: $13.3M
• Headquarters: Pleasanton, CA

How the company plans to use the capital

Graph AI will expand across the United States and Europe while developing modules that automate adverse-event intake, case processing, aggregate reporting, and safety-signal detection with audit trails and human oversight.

Why this matters for GTM teams

The round shows demand for regulated AI systems that reduce manual pharmaceutical workflows without sacrificing validation, inspection readiness, and source traceability.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Graph AI Series A announcement.